The microbiome drug developer took its total series C funding to more than $62m, adding $16.6m from investors including Symbiosis, JSR and Bristol-Myers Squibb.

Frequency Therapeutics, a regenerative medicine developer advancing MIT and Harvard research, has set the range for an initial public offering that will raise $107m if it floats at the high end.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Curamir Therapeutics, a cancer therapeutics developer exploiting Suny research into microRNA, has made its formal debut with $10m of series A funding.

Regnerative medicine developer Frequency Therapeutics has set the range for an initial public offering that will raise $107m if it floats at the high end.

Xinyi Biotech and Legend Star helped supply xenotransplantation technology startup Qihan Biotech with $25.5m to follow $7.8m raised last year.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Cash Capital co-led a series A for Vision Medicals, co-founded by faculty at the Yunnan Province Key Laboratory for Gene Editing.

ETH Zurich’s Versantis picked up series B funding from Zürcher Kantonalbank among other returning investors to bring its total to $20.6m.

Merck & Co has contributed to Themis’ series D round after signing a strategic partnership agreement last month to develop vaccines for undisclosed diseases.